DLA Piper advises Breffi on RUB750m investment from Elbrus Capital

DLA Piper has advised Breffi, a Russian omnichannel pharmaceutical marketing company, on a RUB750 million investment from Elbrus Capital, a Russia and CIS-focused private equity firm.

The funding received from Elbrus Capital will be used to further develop Breffi’s operations, including the scaling up of its services, expansion into adjacent market and the enhancement of IT products development. This is the first time that Breffi has raised capital from an outside investor.

Founded in 2012 by Evgeniy Gordeev and Irina Shramova, both former employees of AstraZeneca, Breffi focuses on the promotion of pharmaceutical brands primarily through the doctors community via remote and digital channels. More than 200,000 doctors use Breffi’s digital services. The company’s clients include over 100 pharmaceutical companies, with the majority being international corporations. Breffi’s revenue in 2021 exceeded RUB500 million.

DLA Piper’s Moscow-based Corporate team was led by partner and Global Co-Chair of Emerging Growth and Venture Capital Leo Batalov, assisted by legal director Andrei Sheetkin, associate Alexandra Braterskaya and paralegal Alexandra Khvorostyanova.